A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

CT.gov Identifier
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
ADARx Pharmaceuticals
Collaborator
N/A
Study Contact Information
Recruiting
Contact Us

Study Details

Diseases
Glomerulonephritis and atypical hemolytic uremic syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome; C3 Glomerulopathy; Complement Factor H Deficiency
IgA nephropathy
Study Drug
ADX-038
Genes
CFI
CFH
Study Dates
Aug 2025 - Dec 2028
Sex
Female & Male
Age
18+ years

Protocol Summary

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.